{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:12:24Z","timestamp":1787987544350,"version":"build-2784847793"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,7]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>TNFRSF14 gene aberrations, common in FL, increase the ability of lymphoma cells to stimulate allogeneic T-cell responses. TNFRSF14 lesions were associated with increased acute GVHD supporting stratified transplantation approaches in the allogeneic setting.<\/jats:p>","DOI":"10.1182\/blood-2015-10-679191","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T03:39:10Z","timestamp":1461296350000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses"],"prefix":"10.1182","volume":"128","author":[{"given":"Eleni","family":"Kotsiou","sequence":"first","affiliation":[{"name":"Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Okosun","sequence":"additional","affiliation":[{"name":"Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Besley","sequence":"additional","affiliation":[{"name":"Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameena","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Matthews","sequence":"additional","affiliation":[{"name":"Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Fitzgibbon","sequence":"additional","affiliation":[{"name":"Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey K.","family":"Davies","sequence":"additional","affiliation":[{"name":"Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111902482928500_B1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111902482928500_B2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1080\/10428190500217312","article-title":"Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma.","volume":"46","author":"Vose","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111902482928500_B3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.","volume":"95","author":"Pi\u00f1ana","year":"2010","journal-title":"Haematologica"},{"issue":"22","key":"2019111902482928500_B4","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis.","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"2019111902482928500_B5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/leu.2011.266","article-title":"High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis.","volume":"26","author":"Launay","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2019111902482928500_B6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1189\/jlb.0910528","article-title":"Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling.","volume":"89","author":"Shui","year":"2011","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2019111902482928500_B7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ni1418","article-title":"B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation.","volume":"8","author":"Krieg","year":"2007","journal-title":"Nat Immunol"},{"issue":"7","key":"2019111902482928500_B8","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3324\/haematol.2010.037481","article-title":"Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells.","volume":"96","author":"Distler","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"2019111902482928500_B9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ejh.12283","article-title":"Na\u00efve subset develops the most important alloreactive response among human CD4+ T lymphocytes in human leukocyte antigen-identical related setting.","volume":"92","author":"Ch\u00e9rel","year":"2014","journal-title":"Eur J Haematol"},{"issue":"12","key":"2019111902482928500_B10","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1084\/jem.20102017","article-title":"Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression.","volume":"207","author":"Albring","year":"2010","journal-title":"J Exp Med"},{"issue":"18","key":"2019111902482928500_B11","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1073\/pnas.92.18.8200","article-title":"Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.","volume":"92","author":"Schultze","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111902482928500_B12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"8","key":"2019111902482928500_B13","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/eji.200636984","article-title":"TLR9 stimulation drives na\u00efve B cells to proliferate and to attain enhanced antigen presenting function.","volume":"37","author":"Jiang","year":"2007","journal-title":"Eur J Immunol"},{"issue":"4","key":"2019111902482928500_B14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/eji.200535744","article-title":"Toll-like receptor stimulation as a third signal required for activation of human naive B cells.","volume":"36","author":"Ruprecht","year":"2006","journal-title":"Eur J Immunol"},{"issue":"6","key":"2019111902482928500_B15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1440-1711.1999.00864.x","article-title":"Divided we stand: tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester.","volume":"77","author":"Lyons","year":"1999","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"2019111902482928500_B16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/TP.0b013e3181861b6c","article-title":"Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity [published correction appears in Transplantation. 2012;93(11):e44].","volume":"86","author":"Davies","year":"2008","journal-title":"Transplantation"},{"issue":"5","key":"2019111902482928500_B17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2141.2012.09106.x","article-title":"T-cell replete fludarabine\/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.","volume":"157","author":"Auer","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111902482928500_B18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111902482928500_B19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111902482928500_B20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111902482928500_B21","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111902482928500_B22","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","article-title":"How I treat refractory acute GVHD.","volume":"109","author":"Deeg","year":"2007","journal-title":"Blood"},{"key":"2019111902482928500_B23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2019111902482928500_B24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"2019111902482928500_B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples.","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer"},{"issue":"9","key":"2019111902482928500_B26","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood.V97.9.2886","article-title":"Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.","volume":"97","author":"Schmaltz","year":"2001","journal-title":"Blood"},{"key":"2019111902482928500_B27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0091-679X(04)75020-7","article-title":"Detection of T-cell degranulation: CD107a and b.","volume":"75","author":"Betts","year":"2004","journal-title":"Methods Cell Biol"},{"issue":"51","key":"2019111902482928500_B28","doi-asserted-by":"crossref","first-page":"20410","DOI":"10.1073\/pnas.0810114105","article-title":"CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.","volume":"105","author":"Yuan","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111902482928500_B29","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.4049\/jimmunol.0902487","article-title":"B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.","volume":"185","author":"Serriari","year":"2010","journal-title":"J Immunol"},{"issue":"2","key":"2019111902482928500_B30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.coi.2013.01.001","article-title":"Lymphotoxin network pathways shape the tumor microenvironment.","volume":"25","author":"Bjordahl","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"13","key":"2019111902482928500_B31","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1073\/pnas.1222093110","article-title":"B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells.","volume":"110","author":"Kobayashi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111902482928500_B32","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2012-11-464685","article-title":"The co-receptor BTLA negatively regulates human V\u03b39V\u03b42 T-cell proliferation: a potential way of immune escape for lymphoma cells.","volume":"122","author":"Gertner-Dardenne","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111902482928500_B33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111902482928500_B34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4049\/jimmunol.1102807","article-title":"B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.","volume":"189","author":"Hobo","year":"2012","journal-title":"J Immunol"},{"issue":"3","key":"2019111902482928500_B35","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.4049\/jimmunol.182.3.1509","article-title":"B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK.","volume":"182","author":"Vendel","year":"2009","journal-title":"J Immunol"},{"issue":"10","key":"2019111902482928500_B36","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.4049\/jimmunol.176.10.5715","article-title":"Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma.","volume":"176","author":"Gururajan","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"2019111902482928500_B37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/0008-5472.CAN-07-3169","article-title":"Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins.","volume":"68","author":"Gupta","year":"2008","journal-title":"Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/1\/72\/1395788\/72.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/1\/72\/1395788\/72.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T07:48:48Z","timestamp":1574149728000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/1\/72\/35368\/TNFRSF14-aberrations-in-follicular-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-10-679191","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}